ArticleJournal of inflammation research2025
Immunoglobulin G N-Glycosylation and Inflammatory Factors: Analysis of Biomarkers for the Diagnosis of Moyamoya Disease.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: N-glycosylation-modified immunoglobulin G (IgG) is crucial for managing the inflammatory response balance and significantly influences the progression of many inflammatory disorders. IgG N-glycosylation has been demonstrated to correlate with many risk factors for moyamoya disease (MMD), such as hypertension, diabetes, and dyslipidemia. This research aimed to evaluate the diagnostic efficacy of IgG N-glycosylation for MMD. Methods: Ultra-high-performance liquid chromatography (UPLC) was employed to examine the properties of IgG N-glycans in blood samples from 116 patients with MMD and 126 controls, resulting in the quantitative determination of 24 initial glycan peaks (GP). Through the Lasso algorithm and multivariate logistic regression analysis, we constructed a diagnostic model based on initial glycans and related inflammatory factors to distinguish MMD patients from healthy individuals. Results: After adjusting for potential confounding variables, including age, fasting blood glucose (FBG), total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), neutrophil count (NEUT), and lymphocyte count (LYM), our study demonstrated significant differences in the characteristics of 6 initial glycans and 16 derived glycans between the MMD cohort and the healthy control group. Based on the above findings, we developed an MMD diagnostic model that combines initial glycans with related inflammatory factors. The curve of receiver operating characteristic (ROC) was utilized to evaluate the model's ability to distinguish MMD patients from healthy subjects. The findings indicated a robust area under the curve (AUC) of 0.963 (95% CI: 0.940, 0.987). Conclusion: This study found that the occurrence and progression of MMD may be associated with decreased levels of sialylation, galactosylation, and fucosylation and increased bisecting GlcNAc. This may be involved in the occurrence of MMD by regulating the balance of inflammation. Therefore, the IgG N-glycosylation is expected to become a potential biomarker for the screening of MMD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.